Orthocell Limited (ASX: OCC) has announced the Orthocell Remplir UK Distributor Appointment, naming LEDA Orthopaedics as the exclusive distributor for its Remplir nerve repair device in the United Kingdom. The appointment positions Orthocell to enter a market valued at US$750 million across the UK and EU, comprising an estimated 500,000 surgical repairs of peripheral nerves annually.
Orthocell secures UK distribution partner ahead of Remplir regulatory approval
The company lodged its regulatory submission with the British Standards Institution (BSI) in December 2025, with approval anticipated in Q3 FY26. Appointing LEDA Orthopaedics ahead of regulatory clearance allows both parties to commence market development activities in preparation for launch, including surgeon engagement, medical education, hospital procurement pathways, and distribution planning.
This strategic approach enables rapid commercial rollout following regulatory approval. LEDA Orthopaedics brings established relationships with orthopaedic surgeons across the UK, particularly those performing upper extremity, trauma, and reconstructive procedures where Remplir’s nerve repair applications are most relevant.
The UK represents a key component of Orthocell’s broader European commercialisation strategy, targeting a combined UK/EU market opportunity estimated at US$750 million based on peripheral nerve repair surgical volumes and procedures.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What is peripheral nerve repair and why does Remplir matter?
Peripheral nerves are the network of nerves outside the brain and spinal cord that control movement and sensation throughout the body. When these nerves are damaged through trauma, surgery, or disease, they often require surgical reconstruction to restore function.
Remplir is a collagen-based medical device designed to support peripheral nerve reconstruction. The device facilitates nerve repair by providing a biological scaffold that guides nerve tissue regeneration during the healing process.
The clinical need is substantial, with an estimated 500,000 peripheral nerve repair procedures performed annually across the UK and EU combined. For investors, this represents a large addressable market with growing surgical volumes and limited competition in the biologics segment of nerve repair technologies.
LEDA Orthopaedics brings established surgeon network and biologics expertise
Founded in 2013 and headquartered in Huntingdon, UK, LEDA Orthopaedics is a specialist distributor of orthopaedic implants and surgical technologies. The company maintains more than 40 direct sales representatives across the UK and has appointed a dedicated Biologics Business Development Manager specifically to support the Remplir launch.
LEDA’s existing portfolio includes technologies from international partners such as Skeletal Dynamics, Checkpoint Surgical, Groupe Lépine, and Integrum. The company’s surgeon call pattern aligns closely with Orthocell’s nerve repair portfolio, as LEDA maintains established relationships with orthopaedic surgeons nationwide who perform complex upper limb and nerve-related procedures.
The distributor also operates dedicated cadaveric training facilities and hands-on surgical training programs, providing infrastructure to support surgeon education around Remplir’s clinical applications.
Jonathan Bloy, LEDA Orthopaedics Co-Founder and Director
“We are delighted to partner with Orthocell to introduce Remplir to the UK market. LEDA Orthopaedics has a strong track record in bringing innovative orthopaedic and surgical technologies to surgeons across the UK, and we believe Remplir represents an important advancement in peripheral nerve repair.”
Commercial strategy supported by proven playbook
The UK rollout of Remplir will be supported by Orthocell’s Australian-based marketing and medical education teams. This approach leverages the same surgeon training programs and clinical evidence that supported successful launches in Australia and the United States, providing a capital-efficient model that utilises existing infrastructure rather than requiring significant additional headcount.
Remplir’s expanding global footprint
Remplir is currently approved and selling across multiple markets, with regulatory approvals secured in Australia, New Zealand, Singapore, the United States, and Hong Kong. First sales in Canada are expected in 2H FY26, with the UK/EU regulatory decision anticipated in Q3 FY26.
| Market | Status |
|---|---|
| Australia | Approved and selling |
| New Zealand | Approved and selling |
| Singapore | Approved and selling |
| United States | Approved and selling |
| Hong Kong | Approved and selling |
| Canada | First sales expected 2H FY26 |
| UK/EU | Regulatory decision anticipated Q3 FY26 |
Each market approval expands Orthocell’s addressable revenue base and validates the regulatory pathway for Remplir across diverse jurisdictions. The progressive rollout demonstrates the company’s ability to secure approvals in major markets while building commercial infrastructure to support multi-territory distribution.
Strong balance sheet to fund global expansion
Orthocell reported approximately $49.4 million in cash reserves at 31 December 2025, providing a strong balance sheet to support its global distribution strategy and ongoing Remplir commercialisation. The cash position comprises:
- $7.4 million in cash and cash equivalents
- $42 million in term deposits with maturities ranging from 3 to 12 months
This funding position removes near-term capital risk and provides runway to execute the multi-market launch strategy, advance regulatory programs in the UK and Europe, and drive commercial rollout across existing and new markets.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What’s next for Orthocell
Near-term catalysts for (ASX: OCC) include:
- UK regulatory decision anticipated Q3 FY26
- Canada first sales expected 2H FY26
- Market development activities commencing immediately with LEDA Orthopaedics, including surgeon education, hospital procurement engagement, and distribution planning
The appointment of LEDA Orthopaedics ahead of regulatory approval positions Orthocell to commence market preparation activities that support rapid commercial launch following BSI clearance.
Paul Anderson, Orthocell CEO and MD
“The UK represents an important growth market for Remplir, and we are pleased to partner with LEDA Orthopaedics to support our future commercial rollout. LEDA brings deep expertise in orthopaedic distribution and established relationships with surgeons performing complex upper limb and nerve repair procedures. Their network and clinical focus align closely with Remplir’s target surgeon base. Appointing LEDA ahead of regulatory approval allows us to prepare the market through surgeon education and engagement, positioning Orthocell for a rapid commercial launch following approval.”
Want the Next Biotech Breakout in Your Inbox?
Join 20,000+ investors receiving FREE ASX healthcare and biotech alerts within minutes of release, complete with breaking news and in-depth analysis. Click the “Free Alerts” button at StockWire X to stay ahead on market-moving announcements the moment they break.